GO
Loading...

Pharmaceuticals

More

  • Lightning Round: Medco, Amgen, Yum! and More Thursday, 28 Feb 2008 | 8:12 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Bayer Misses Forecasts; CEO Upbeat on 2008 Thursday, 28 Feb 2008 | 1:12 PM ET

    German drugs and chemicals group Bayer missed fourth-quarter earnings expectations Thursday, sending shares 4.7 percent lower on the DAX, but CEO Werner Wenning told CNBC he remains optimistic about the company’s outlook for this year.

  • Lechleiter Likes Lilly--A Lot Thursday, 28 Feb 2008 | 9:50 AM ET

    When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.

  • Major European Companies Report Mixed Earnings Thursday, 28 Feb 2008 | 6:53 AM ET

    European earnings failed to drive broader European markets higher, as disappointing numbers from bigger names and cautious guidance mostly pushed shares in reporting companies lower.

  • Bayer Profit Misses Forecasts; Upbeat on 2008 Thursday, 28 Feb 2008 | 4:09 AM ET

    Bayer's quarterly profits missed market expectations, but the German drugs and chemicals group was upbeat about 2008 and said its healthcare and agrochemicals units would drive earnings.

  • Onyx Hires New CEO--But Here's What You Won't Find In PR Wednesday, 27 Feb 2008 | 3:28 PM ET

    Recently I've blogged and raised the question in an interview about whether Onyx Pharmaceuticals might be having a tough time finding a new leader. Well, nearly six months since longtime Chairman and CEO Hollings Renton announced his plans to retire this year, the biotech company has filled the spot.

  • Prana Biotechnology: Why I Wanted To Do Their Story Tuesday, 26 Feb 2008 | 1:13 PM ET

    I often get pitched by PR people who want me to do a story on their micro-cap biotech company. And I almost always turn them down. I know that most of the sector toils in the eight and nine digit market value space and that there's a bit of a Catch-22 at work.

  • Pfizer's CEO Kindler Being Kind To Hillary--Again Monday, 25 Feb 2008 | 1:37 PM ET

    According to The Center for Responsive Politics' web site Pfizer Chairman and CEO Jeff Kindler has opened his wallet again for Sen. Hillary Clinton. You can see his latest "give" here. Twice now within the past year Kindler has given the maximum amount ($2,300) an individual can contribute to a candidate.

  • Roche Outlook, Stock Buoyed by Avastin Approval Monday, 25 Feb 2008 | 12:48 PM ET

    Analysts raised forecasts for Roche Holding on Monday after U.S. regulators approved its Avastin drug for treating advanced breast cancer, adding a potentially significant new revenue source.

  • Genentech: How It Got Its Groove Back Monday, 25 Feb 2008 | 10:42 AM ET

    I always prefer it when pharmaceutical/biotech execs and analysts can break out of their scientific/financial jargon and give good soundbites or quotes. So, among the flurry of research notes I've received over the weekend and this morning on the Genentech Avastin news the award goes to Rodman & Renshaw's Mike King who writes, "The biotech leader has its groove back."

  • Breast Cancer Drug Avastin Approved by FDA Friday, 22 Feb 2008 | 4:57 PM ET

    A drug made by Genentech  received federal approval on Friday to treat breast cancer, a decision that could represent a major shift in standards for assessing the effectiveness of cancer medicines.

  • Genentech's Avastin Gets "Qualified" Win From FDA Friday, 22 Feb 2008 | 4:53 PM ET

    Shortly before the closing bell trading in shares of Genentech was halted for news pending. Then, right after the bell the company issued this press release announcing the Food and Drug Administration has granted "accelerated approval" to Genentech's Avastin for use on breast cancer.

  • Waiting For FDA--In the Meantime, Your Emails Friday, 22 Feb 2008 | 12:03 PM ET

    As we sit here closely monitoring the wires and waiting for word out of Genentech and/or the FDA about a decision on Avastin for breast cancer, it seemed like as good a time as any to once again post some samples of a flood of recent emails from readers--the good, the bad and the ugly.

  • Merck, SGP's "Enhance" Study No "Late Breaker" At ACC Thursday, 21 Feb 2008 | 4:36 PM ET

    The results of the controversial study called "Enhance" of the cholesterol drug Vytorin from Merck and Schering-Plough will not be presented as a prestigious "late breaker" at the upcoming annual meeting of the American College of Cardiology.

  • Genentech's Avastin: Will FDA Give It An "Oscar"? Thursday, 21 Feb 2008 | 11:25 AM ET

    Who needs Oscar ballots? Biotech investing wonks/nerds (and I'm not suggesting I am one) might wanna start an office pool about when and what the FDA's decision will be on Genentech's drug Avastin for breast cancer.

  • Coffee Talk With Amgen And Roche Wednesday, 20 Feb 2008 | 3:15 PM ET

    Perhaps this item belongs in the "Funny Business" blog of my witty colleague Jane Wells, but when I saw this headline cross the Dow Jones Newswire this afternoon under the "Market Talk" blurb they move several times during the trading day, I just had to throw it up on my blog. I didn't know DJ had hired "Linda Richman" to write copy, or maybe Mike Myers needs a little extra income.

  • Pfizer Wheelin' and Dealin' For Encysive's Thelin Wednesday, 20 Feb 2008 | 10:54 AM ET

    The world's biggest drug company is spending chump change to take out a little biotech at a 118 percent premium. Pfizer, which has a cash hoard of more than $20 billion, is plunking down a paltry (for Pfizer, that is) $195 million in cash money to buy Encysive Pharmaceuticals.

  • Black Tuesday for Onyx Tuesday, 19 Feb 2008 | 12:27 PM ET

    Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver cancer and the stock doubled in one day, the biopharmaceutical company is providing an example of the ups and downs of drug development and biotech investing.

  • European Stocks Rally as Banks Surge Monday, 18 Feb 2008 | 12:13 PM ET

    European markets were firmly in positive territory Monday, as banking stocks gained following news Northern Rock was to be nationalized. Oil-related firms also jumped as crude prices neared one-month highs.

  • Hedge Fund Gets Back To Me On Dendreon Holdings Friday, 15 Feb 2008 | 3:19 PM ET

    Even though I'm off today I, like a lot of folks, couldn't help checking my landline voicemail at work. And much to my surprise one of the messages was from Mark Gottlieb, the Chief Compliance Officer at Visium Asset Mgt. I referred to him in yesterday's post.